Original ArticlesVERTEPORFIN PHOTODYNAMIC THERAPY INVOLVING THE OPTIC NERVE FOR PERIPAPILLARY CHOROIDAL NEOVASCULARIZATIONBERNSTEIN, PAUL S. MD, PHD; HORN, RACHAEL SUE MDAuthor Information From Moran Eye Center, University of Utah, Salt Lake City. Supported by Research to Prevent Blindness, New York, New York. No conflict of interest is reported for any of the authors. Reprint requests: Paul S. Bernstein, MD, PhD, Moran Eye Center, University of Utah, 65 Medical Drive, Salt Lake City, UT 84132; e-mail: email@example.com Retina: January 2008 - Volume 28 - Issue 1 - p 81-84 doi: 10.1097/IAE.0b013e31815e9351 Buy Metrics AbstractIn Brief Background: To report the outcome of consecutive patients treated with verteporfin photodynamic therapy in which the treatment zone overlapped the optic nerve. Methods: Retrospective interventional case series with chart review of seven patients with peripapillary choroidal neovascularization secondary to age-related macular degeneration treated with standard-dose verteporfin photodynamic therapy. Results: The first of seven patients had excellent visual outcome with visual acuity measurement improved from 20/80 to 20/20 at 6 months post-treatment which remained stable for over 2 years. All remaining patients had improvement of visual acuity with resolution of peripapillary hemorrhage. Only two of the seven patients required more than one treatment with verteporfin photodynamic therapy. Conclusion: Peripapillary choroidal neovascular membranes can be successfully treated with standard-dose verteporfin photodynamic therapy, often with resolution of neovascularization with one treatment. There was no evidence of optic nerve damage from the intervention. Peripapillary choroidal neovascular membranes secondary to age-related macular degeneration can be successfully and safely treated with standard-dose photodynamic therapy, often with resolution of the neovascular membrane after one treatment. In this case series, there was no evidence of optic nerve damage from the intervention. © The Ophthalmic Communications Society, Inc.